Pharmaceutics Webinar | Development of Physiologically Based Pharmacokinetic and Biopharmaceutics Analysis and Modelling (PBPK and PBBM)
the chair
Physiologically Based Pharmacokinetic (PBPK) Modeling involves simulating the absorption, distribution, metabolism, and excretion (ADME) of drugs throughout the body. So, PBPK modeling is a mathematical tool which can describe the drug concentration in an organism using compartments that correspond to the different tissues and takes into consideration the physiology of this organism to parameterize the model.
Physiologically Based Biopharmaceutics Modeling (PBBM) is an established analysis mechanistically linking in vitro drug product performance (like dissolution) to in vivo absorption and bioavailability.
These types of models have become useful in drug development since their discovery, and are particularly important in early phases, when in vitro data and physicochemical properties can be used to obtain plasma profiles, which would be later validated in vivo, and until the clinical development phases, in which simulations can be used to describe drug performance in special populations.
Date: 22 July 2025
Time: 1:00 pm CEST | 7:00 am EDT | 7:00 pm CST Asia
Webinar ID: 815 2324 5665
Webinar Secretariat: journal.webinar@mdpi.com
Meet the Event Chair
Meet Our Speakers
Dr. Bart Hens
Drug Product Design Biomodeler / Biopharmaceutics Principal, Pfizer, United Kingdom;
Bart Hens holds a Ph.D. in Pharmaceutical Sciences from the University of Leuven, where he developed a strong foundation in biopharmaceutics. His expertise was further deepened during his postdoctoral training under the mentorship of Dr. Gordon L. Amidon at the University of Michigan, Ann Arbor, where he focused on advancing the understanding of oral drug absorption. Currently, he serves as a Principal Scientist in Biopharmaceutics and Biomodeling at Pfizer. In this role, he successfully established a global biopharmaceutics network that connects scientific hubs across the United States, the United Kingdom, and India to foster collaboration and knowledge exchange among biopharmaceutical scientists and modelers. His current research explores the integration of in vitro dissolution behavior with the in vivo absorbed fraction to develop robust in vitro–in vivo correlations (IVIVC).
Prof. Dr. Marival Bermejo
Pharmacokinetics and Pharmaceutical Technology, Miguel Hernandez University, Spain;
Marival Bermejo is a full professor of Pharmacy and Pharmaceutical Technology in Spain at the Miguel Hernández University of Elche. Her current research is focused on the validation of in situ and in vitro models of absorption and dissolution for predicting oral permeability and on the development of cellular models of the blood–brain barrier. Professor Marival Bermejo has coordinated and participated in numerous research projects funded by the European Commission and the Ministry of Science and Technology in Spain. Dr. Bermejo has published more than 150 original research articles, several review papers, 10 book chapters, and a book on bio-pharmaceutical methodologies. In 2022, an analysis by Elsevier based on the Scopus database to evaluate the impact of scientific publications indicated that Professor Bermejo was among the top 2% of the world's most-cited scientific authors. She is an external expert for the Spanish Agency of Medicines and Health Products and the European Medicines Agency (EMA). Currently, she is a member of Teaching and Research at the College of Pharmacists in Alicante, Spain.
Dr. Yasuhiro (Hiro) Tsume
Merck Research Laboratories, 126 E. Lincoln Ave, Rahway NJ 07065, USA;
Dr. Yasuhiro (Hiro) Tsume is a Principal Scientist at Merck & Co. He received his Ph.D. degree in 2006 from the University of Michigan, supervised by Prof. Gordon L Amidon. From 2006 to 2017, he worked as a post-doctoral research fellow, a pharmacokinetics (PK) core manager, and became an independent researcher at the University of Michigan. He joined Merck in 2018 and has been working in the biopharmaceutics field. His research interests include drug dissolution, drug absorption, drug metabolism, drug-targeting delivery, and IVIVC. He has especially been focusing on IVIVC and the in vivo prediction of oral drug dissolution/absorption by in vitro studies. He has been involved in different scientific groups to promote in vivo predictive dissolution system and several organizations to organize the international conferences. He has published over 70 original research articles and book chapters.
Sponsors and Partners
Organizer
The webinar was hosted via Zoom and required registration to attend. The full recording can be found below. In order to learn about future webinars, you can sign up to our newsletter by clicking “Subscribe” at the top of the page.
"Development of Physiologically Based Pharmacokinetic (PBPK) Modeling"
Guest Editor: Dr. Bárbara Sánchez-Dengra and Prof. Dr. Isabel Gonzalez-Alvarez
Deadline for Manuscript Submission: 30 September 2025